Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019
Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019
复制标题
DOI：
10.1111/joim.13089
复制
发表时间：
2020-06-17
影响因子：
11.1
通讯作者：
Saussez, Sven
中科院分区：
文献类型：
--
作者：
Lechien, Jerome R.;Chiesa-Estomba, Carlos M.;Saussez, Sven
背景欧洲轻中度COVID-19感染患者的临床表现仍不清楚。目的研究欧洲COVID-19的临床表现。方法从18家欧洲医院招募了COVID-19诊断阳性的患者。流行病学和临床数据通过标准化问卷调查获得。贝叶斯分析用于分析结果之间的关系。结果共有1，420名患者完成了研究（962名女性，占医务人员的30.7%）。患者的平均年龄为39.17 ± 12.09岁。最常见的症状是头痛（70.3%）、嗅觉丧失（70.2%）、鼻塞（67.8%）、咳嗽（63.2%）、乏力（63.3%）、肌痛（62.5%）、流涕（60.1%）、味觉障碍（54.2%）和咽喉痛（52.9%）。45.4%报告发热。轻度至中度治愈患者的COVID-19症状平均持续时间为11.5 +/- 5.7天。症状的患病率根据年龄和性别而显著不同。年轻患者更经常有耳，鼻和咽喉的投诉，而老年人往往表现为发烧，疲劳和食欲不振。嗅觉丧失、头痛、鼻塞和疲劳在女性患者中更常见。嗅觉丧失是轻中度COVID-19患者的一个关键症状，与鼻塞和鼻溢无关。在37.5%的治愈患者中，嗅觉丧失持续至少7天。结论轻中度COVID-19的临床表现根据患者的年龄和性别特征而存在很大差异。嗅觉功能障碍似乎是轻至中度COVID-19的一个重要的被低估的症状，需要得到世卫组织的认可。
Background The clinical presentation of European patients with mild-to-moderate COVID-19 infection is still unknown. Objective To study the clinical presentation of COVID-19 in Europe. Methods Patients with positive diagnosis of COVID-19 were recruited from 18 European hospitals. Epidemiological and clinical data were obtained through a standardized questionnaire. Bayesian analysis was used for analysing the relationship between outcomes. Results A total of 1,420 patients completed the study (962 females, 30.7% of healthcare workers). The mean age of patients was 39.17 +/- 12.09 years. The most common symptoms were headache (70.3%), loss of smell (70.2%), nasal obstruction (67.8%), cough (63.2%), asthenia (63.3%), myalgia (62.5%), rhinorrhea (60.1%), gustatory dysfunction (54.2%) and sore throat (52.9%). Fever was reported by 45.4%. The mean duration of COVID-19 symptoms of mild-to-moderate cured patients was 11.5 +/- 5.7 days. The prevalence of symptoms significantly varied according to age and sex. Young patients more frequently had ear, nose and throat complaints, whereas elderly individuals often presented fever, fatigue and loss of appetite. Loss of smell, headache, nasal obstruction and fatigue were more prevalent in female patients. The loss of smell was a key symptom of mild-to-moderate COVID-19 patients and was not associated with nasal obstruction and rhinorrhea. Loss of smell persisted at least 7 days after the disease in 37.5% of cured patients. Conclusion The clinical presentation of mild-to-moderate COVID-19 substantially varies according to the age and the sex characteristics of patients. Olfactory dysfunction seems to be an important underestimated symptom of mild-to-moderate COVID-19 that needs to be recognized as such by the WHO.